Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

Critical elements of leading Alzheimer’s study possibly fraudulent

The highly influential paper, first published in 2006, has helped guide billions of dollars in US federal research into the disease

The Guardian - US

Biogen Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

IBD Stock Of The Day XBI: How To Trade Blazing-Hot Biotech Stocks Without Getting Burned

The SPDR S&P Biotech ETF is the IBD Stock Of The Day. XBI stock has shucked off near-term resistance on enthusiasm for biotech stocks.

Investors Business Daily

Stock Market Adds To Weekly Gains; Tesla Set To Report

The stock market erased early losses to trade higher by midday on the strength of robust earnings from Netflix and others.

Investors Business Daily

Dow Jones Falls As Netflix Jumps On Earnings; Tesla Earnings Up Next

The Dow Jones Industrial Average fell Wednesday, as Netflix stock jumped on earnings results. Tesla earnings are due out after the close.

Investors Business Daily

Biogen's Quarterly Report Was 'Fine' — Here's Why Shares Toppled

Biogen's second-quarter report was "fine," one analyst said. But without an update on its strategy for life after Aduhelm, Biogen stock fell.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform

Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.

Benzinga

Peering Into Biogen's Recent Short Interest

Biogen's (NASDAQ:BIIB) short percent of float has risen 9.27% since its last report. The company recently reported that it has 2.41 million shares sold short, which is 1.65% of all regular shares that are available for trading.

Benzinga

Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.63% on an annualized basis producing an average annual return of 10.11%. Currently, Biogen has a market capitalization of $31.20 billion.

Benzinga

3 Biotech Stocks to Buy Now

Biotech stocks are starting to move higher as longer-term rates decline. The sector is very cheap with strong long-term fundamentals. Amgen (AMGN), Biogen (BIIB), and Bio-Techne (TECH) are 3 top biotech stocks that investors should consider buying.

StockNews.com

Commentary: Overhyped Alzheimer’s treatments betrayed patients’ hopes. Here’s how science should change

America’s science policies are changing. America’s scientists need to change with them. The recent controversies over the Food and Drug Administration’s accelerated approval of an Alzheimer’s treatment are a lesson in the costs of failing to do so.

Los Angeles Times

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement

Biogen Inc. (NASDAQ:BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ:KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of Nuclear Export compound KPT-350 and certain related assets to Biogen. KPTI received an upfront payment…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

ABC News

Why the world's still waiting for a dementia cure, and what we can do in the meantime

Many researchers agree that Alzheimer's disease actually starts decades before thinking and memory start to decline. What can we do about it?

Benzinga

$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today

Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.47% on an annualized basis producing an average annual return of 9.5%. Currently, Biogen has a market capitalization of $30.05 billion.

Salon

Biden HHS hands a "gift to McConnell"

Latest HHS move should alarm "every Congressional Democrat who wants to keep their seat in November"

Investors Business Daily

Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same

Sage stock popped Wednesday after its Biogen-partnered treatment for postpartum depression met every goal in a final-phase study.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.1% on an annualized basis producing an average annual return of 10.04%. Currently, Biogen has a market capitalization of $29.43 billion.

Investors Business Daily

How Long It'll Take 10 Crushed Stocks Like Netflix To Rebound

Waiting for Netflix and other fallen S&P 500 stocks to bounce back from their epic crashes? Hope you have a big bag of popcorn and lots of time to wait — like four years.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Is Eyeing Not One — But Two — Multibillion-Dollar Opportunities

Eli Lilly is the IBD Stock Of The Day after "transformative" data in obesity helped LLY stock retain its recent breakout.

Investors Business Daily

Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment

Biogen stock popped Tuesday after the company's partner, Eisai, finished submitting its application for an experimental Alzheimer's drug.

Benzinga

Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug

Eisai Co Ltd (OTC:ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD. Eisai is collaborating with Biogen Inc (NASDAQ:BIIB) for drug development. Eisai has requested a Priority Review, while the lecanemab Phase 3…

Benzinga

Looking Into Biogen's Return On Capital Employed

According to Benzinga Pro, during Q1, Biogen (NASDAQ:BIIB) earned $218.50 million, a 1165.85% increase from the preceding quarter. Biogen's sales decreased to $2.53 billion, a 7.39% change since Q4.

Benzinga

Read Why Biogen Shares Are Trading Higher After Q1 Earnings

Biogen Inc (NASDAQ:BIIB) posted Q1 sales of 2.53 billion, beating the consensus of $2.49 billion, down 6% Y/Y. Multiple sclerosis (MS) revenue, including royalties on sales of Ocrevus, of $1.79 billion decreased by 3%. Spinraza's revenue of $441 million decreased 9% at actual currency and 6% at constant currency. Aduhelm's revenue was…

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.